Senseonics Holdings, Inc. (SENS)
| Market Cap | 188.72M |
| Revenue (ttm) | 22.21M |
| Net Income (ttm) | -80.33M |
| Shares Out | 595.33M |
| EPS (ttm) | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,954,419 |
| Open | 0.300 |
| Previous Close | 0.318 |
| Day's Range | 0.296 - 0.328 |
| 52-Week Range | 0.275 - 0.750 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+530.92%) |
| Earnings Date | Nov 7, 2024 |
About SENS
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare provider... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for SENS stock is "Strong Buy" and the 12-month stock price forecast is $2.0.
News
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Of...
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaram...
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia ...
Eversense 365 Launches in the US: One Year. One CGM.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's onl...
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantabl...
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable...
Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group, IR Tim Goodnow - President and CEO Rick Sullivan...
Senseonics Holdings, Inc. Reports Second Quarter 2024 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for August 8, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association's 84th Scientific Sessions
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in the Sidoti Small Cap Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. (SENS) Q1 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:11 PM ET Senseonics Holdings, Inc. (NYSE:SENS) Q1 2024 Earnings Conference Call May 13, 2024, 16:30 AM ET Company Participants Tim Goodnow - President and CEO Rick...
Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
GERMANTOWN, Md. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantab...
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in Upcoming Conferences
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Eversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Eversense® CGM System Receives iCGM Designation by the US FDA.
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PARSIPPANY, N.J. , March 12, 2024 /PRNewswir...
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. (SENS) Q4 2023 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...